WO2005050202A3 - Biological materials and uses thereof - Google Patents

Biological materials and uses thereof Download PDF

Info

Publication number
WO2005050202A3
WO2005050202A3 PCT/GB2004/004781 GB2004004781W WO2005050202A3 WO 2005050202 A3 WO2005050202 A3 WO 2005050202A3 GB 2004004781 W GB2004004781 W GB 2004004781W WO 2005050202 A3 WO2005050202 A3 WO 2005050202A3
Authority
WO
WIPO (PCT)
Prior art keywords
smad
tieg
test compound
expression
providing
Prior art date
Application number
PCT/GB2004/004781
Other languages
French (fr)
Other versions
WO2005050202A2 (en
Inventor
Nadia Abdel Wahab
Roger Maxwell Mason
Original Assignee
Imp College Innovations Ltd
Nadia Abdel Wahab
Roger Maxwell Mason
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imp College Innovations Ltd, Nadia Abdel Wahab, Roger Maxwell Mason filed Critical Imp College Innovations Ltd
Priority to EP04798502A priority Critical patent/EP1690098A2/en
Priority to JP2006540575A priority patent/JP2007515161A/en
Priority to AU2004292012A priority patent/AU2004292012A1/en
Priority to CA002546397A priority patent/CA2546397A1/en
Publication of WO2005050202A2 publication Critical patent/WO2005050202A2/en
Publication of WO2005050202A3 publication Critical patent/WO2005050202A3/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5023—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects on expression patterns
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5041—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving analysis of members of signalling pathways
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

The invention provides a method for identifying and/or making compounds for use in reducing and/or preventing fibrosis, comprising the steps: providing a cell type capable of expressing TIEG and/or Smad-7; providing a test compound; providing an amount of CTGF or a functional equivalent thereof, exposing the cell type to the test compound; subsequently or simultaneously exposing the cell type to the CTGF or functional equivalent thereof; detecting and/or measuring the expression of Smad-7 and TIEG; and comparing the amount of Smad-7 and/or TIEG expressed in the presence of the test compound with the amount of Smad-7 and/or TIEG produced detected and/or measured in the absence of a test compound; determining if a compound reduces and/or prevents fibrosis on the basis that it causes no change or an increase in Smad-7 expression and/or no change or a decrease in TIEG expression. There is also provided compounds for reducing and/or preventing fibrosis and uses of such compounds.
PCT/GB2004/004781 2003-11-18 2004-11-12 Biological materials and uses thereof WO2005050202A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP04798502A EP1690098A2 (en) 2003-11-18 2004-11-12 Biological materials and uses thereof
JP2006540575A JP2007515161A (en) 2003-11-18 2004-11-12 Biological substances and their use
AU2004292012A AU2004292012A1 (en) 2003-11-18 2004-11-12 Biological materials and uses thereof
CA002546397A CA2546397A1 (en) 2003-11-18 2004-11-12 Biological materials and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0326778.8 2003-11-18
GBGB0326778.8A GB0326778D0 (en) 2003-11-18 2003-11-18 Biological materials and uses thereof

Publications (2)

Publication Number Publication Date
WO2005050202A2 WO2005050202A2 (en) 2005-06-02
WO2005050202A3 true WO2005050202A3 (en) 2005-11-03

Family

ID=29763970

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2004/004781 WO2005050202A2 (en) 2003-11-18 2004-11-12 Biological materials and uses thereof

Country Status (7)

Country Link
EP (1) EP1690098A2 (en)
JP (1) JP2007515161A (en)
CN (1) CN1906490A (en)
AU (1) AU2004292012A1 (en)
CA (1) CA2546397A1 (en)
GB (1) GB0326778D0 (en)
WO (1) WO2005050202A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8946172B2 (en) 2008-08-25 2015-02-03 Excaliard Pharmaceuticals, Inc. Method for reducing scarring during wound healing using antisense compounds directed to CTGF
CN103429270B (en) * 2008-08-25 2016-11-23 埃克斯雷德制药有限公司 Stop antisense nucleotide of Connective Tissue Growth Factor and application thereof
SI2670411T1 (en) 2011-02-02 2019-06-28 Excaliard Pharmaceuticals, Inc. Antisense compounds targeting connective tissue growth factor (ctgf) for use in a method of treating keloids or hypertrophic scars
CN104487574B (en) 2012-04-18 2017-07-07 诺格尔制药有限公司 Treatment diabetes and/or the method for promoting survival after pancreatic islets transplantation
CN117677692A (en) * 2021-05-21 2024-03-08 江苏九济华生医药科技研究院有限公司 Cell strain for TGF beta detection and high-precision TGF beta detection method

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035936A1 (en) * 1998-12-14 2000-06-22 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
US6555322B1 (en) * 1999-08-27 2003-04-29 Fibrogen, Inc. α2-macroglobulin receptor as a receptor for CTGF
WO2005050203A2 (en) * 2003-11-18 2005-06-02 Imperial College Innovations Limited The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000035936A1 (en) * 1998-12-14 2000-06-22 University Of Miami Connective tissue growth factor fragments and methods and uses thereof
US6555322B1 (en) * 1999-08-27 2003-04-29 Fibrogen, Inc. α2-macroglobulin receptor as a receptor for CTGF
WO2005050203A2 (en) * 2003-11-18 2005-06-02 Imperial College Innovations Limited The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ABDEL WAHAB N ET AL: "Modulation of the TGFbeta/Smad signaling pathway in mesangial cells by CTGF/CCN2", EXPERIMENTAL CELL RESEARCH, SAN DIEGO, CA, US, vol. 307, no. 2, 15 July 2005 (2005-07-15), pages 305 - 314, XP004927162, ISSN: 0014-4827 *
JOHNSEN STEVEN A ET AL: "TGFbeta inducible early gene enhances TGFbeta/Smad-dependent transcriptional responses", ONCOGENE, vol. 21, no. 37, 22 August 2002 (2002-08-22), pages 5783 - 5790, XP002339186, ISSN: 0950-9232 *
NAKAO ATSUHITO ET AL: "Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice", JOURNAL OF CLINICAL INVESTIGATION, vol. 104, no. 1, July 1999 (1999-07-01), pages 5 - 11, XP002339185, ISSN: 0021-9738 *

Also Published As

Publication number Publication date
CN1906490A (en) 2007-01-31
WO2005050202A2 (en) 2005-06-02
CA2546397A1 (en) 2005-06-02
AU2004292012A1 (en) 2005-06-02
EP1690098A2 (en) 2006-08-16
GB0326778D0 (en) 2003-12-24
JP2007515161A (en) 2007-06-14

Similar Documents

Publication Publication Date Title
WO2006073738A3 (en) Colorimetric sensors constructed of diacetylene materials
WO2008041953A3 (en) Dengue diagnosis and treatment
WO2002027326A3 (en) Method and kit for the transderaml determination of analyte concentration in blood
WO2004091387A3 (en) Dual measurement analyte detection system
WO2007127749A3 (en) Predicting mortality and detecting severe disease
AU1725200A (en) Simultaneous determination of equilibrium and kinetic properties
TW200502550A (en) Colorimetric sensors constructed of diacetylene materials
EP1359417A3 (en) Devices and methods for analyte concentration determination
WO2003102218A3 (en) Hybrid microcantilever sensors
WO2006066274A3 (en) Breath-based sensors for non-invasive molecular detection
PT1776587E (en) Use of c3a and derivatives thereof as biomarker for colorectal adenoma and/or carcinoma ; diagnosis methods and assays using the same
WO2003043487A3 (en) Method of using a non-antibody protein to detect and measure an analyte
WO2004099432A3 (en) Identification of biomarkers for detecting pancreatic cancer
WO2005079304A3 (en) Method and system to measure characteristics of a film disposed on a substrate
WO2007079843A3 (en) Test strip and method for measuring an analyte concentration in a sample of a biological fluid
WO2001075450A3 (en) Fluorescent lifetime assays for non-invasive quantification of analytes
ATE532063T1 (en) ELECTROCHEMICAL BIOSENSOR
WO2004057314A3 (en) Polarisation interferometric method and sensor for detecting a chemical substance
WO2004000884A3 (en) Compositions and methods for apo-b48 and apo-b100 assay
WO2007088355A3 (en) Sepsis test
WO2004072606A3 (en) Polymeric membranes for use in electrochemical sensors
AU2003215467A1 (en) Method and device for predicting cardiovascular events
WO2003057014A3 (en) Biomarkers for detecting ovarian cancer
WO2005050203A3 (en) The methods for screening using ctgf and trka receptor for the identification of compounds for use in treatment of fibrosis
WO2005050202A3 (en) Biological materials and uses thereof

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2546397

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2006540575

Country of ref document: JP

Ref document number: 547297

Country of ref document: NZ

Ref document number: 2821/DELNP/2006

Country of ref document: IN

NENP Non-entry into the national phase

Ref country code: DE

WWW Wipo information: withdrawn in national office

Ref document number: DE

WWE Wipo information: entry into national phase

Ref document number: 2004292012

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2004798502

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004292012

Country of ref document: AU

Date of ref document: 20041112

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004292012

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 200480040636.3

Country of ref document: CN

WWP Wipo information: published in national office

Ref document number: 2004798502

Country of ref document: EP